Hiroshi Ishii

Computer Science · Physical Sciences

74h-index25.8kcitations406works2.32yr avg
OpenAlex↗ORCID↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Interactive and Immersive Displays(194), Tactile and Sensory Interactions(107), Augmented Reality Applications(91), Dementia and Cognitive Impairment Research(47), Innovative Human-Technology Interaction(43)

Publications406 total

Atlas of Human-AI Interaction (v1): An Interactive Meta-Science Platform for Large-Scale Research Literature Sensemaking
arXiv (Cornell University)·2025Open Access
A framework for handweaving robotic textiles with liquid crystal elastomer fibers
Scientific Reports·2025· 3 citedOpen Access
Current status of the cost burden of first-line systemic treatment for patients with advanced hepatocellular carcinoma in Japan, 2021–22
Japanese Journal of Clinical Oncology·2024· 4 citedOpen Access
Reducing the use of psychotropics in a convalescent rehabilitation ward
Neuropsychopharmacology Reports·2023· 2 citedOpen Access
Living Bits and Radical Aminos: A Workshop on Bio-Digital Interfaces for Human-Computer Interaction
2023· 10 cited
Supplementary Figure Legend from Phase I Trial of a Glypican-3–Derived Peptide Vaccine for Advanced Hepatocellular Carcinoma: Immunologic Evidence and Potential for Improving Overall Survival
2023Open Access
Supplementary Figure 1 from Phase I Trial of a Glypican-3–Derived Peptide Vaccine for Advanced Hepatocellular Carcinoma: Immunologic Evidence and Potential for Improving Overall Survival
2023Open Access
Data from Phase I Trial of a Glypican-3–Derived Peptide Vaccine for Advanced Hepatocellular Carcinoma: Immunologic Evidence and Potential for Improving Overall Survival
2023Open Access
Supplementary Figure 1 from Phase I Trial of a Glypican-3–Derived Peptide Vaccine for Advanced Hepatocellular Carcinoma: Immunologic Evidence and Potential for Improving Overall Survival
2023Open Access
Supplementary Table 2 from Phase I Trial of a Glypican-3–Derived Peptide Vaccine for Advanced Hepatocellular Carcinoma: Immunologic Evidence and Potential for Improving Overall Survival
2023Open Access
Supplementary Figure 2 from Phase I Trial of a Glypican-3–Derived Peptide Vaccine for Advanced Hepatocellular Carcinoma: Immunologic Evidence and Potential for Improving Overall Survival
2023Open Access
Supplementary Table 1 from Phase I Trial of a Glypican-3–Derived Peptide Vaccine for Advanced Hepatocellular Carcinoma: Immunologic Evidence and Potential for Improving Overall Survival
2023Open Access
Supplementary Figure 2 from Phase I Trial of a Glypican-3–Derived Peptide Vaccine for Advanced Hepatocellular Carcinoma: Immunologic Evidence and Potential for Improving Overall Survival
2023Open Access
Data from Phase I Trial of a Glypican-3–Derived Peptide Vaccine for Advanced Hepatocellular Carcinoma: Immunologic Evidence and Potential for Improving Overall Survival
2023Open Access
Supplementary Table 2 from Phase I Trial of a Glypican-3–Derived Peptide Vaccine for Advanced Hepatocellular Carcinoma: Immunologic Evidence and Potential for Improving Overall Survival
2023Open Access
Supplementary Figure Legend from Phase I Trial of a Glypican-3–Derived Peptide Vaccine for Advanced Hepatocellular Carcinoma: Immunologic Evidence and Potential for Improving Overall Survival
2023Open Access
Supplementary Table 1 from Phase I Trial of a Glypican-3–Derived Peptide Vaccine for Advanced Hepatocellular Carcinoma: Immunologic Evidence and Potential for Improving Overall Survival
2023Open Access
Intrahepatic cholangiocarcinoma with a liver abscess due to hepatic actinomycosis
Surgical Case Reports·2023· 3 citedOpen Access
ASO Visual Abstract: Incidence of Metachronous Remnant Gastric Cancer After Proximal Gastrectomy with the Double-Flap Technique (rD-FLAP-rGC Study): A Multicenter Retrospective Study
Annals of Surgical Oncology·2023
Clinical Significance of Subcellular Localization of Maspin in Breast Carcinoma: An Immunohistochemical Study Using Two Different Antibodies
Yonago acta medica·2023· 1 citedOpen Access
page 1 of 21Next →

Frequent Co-authors

Brygg Ullmer(8), Jifei Ou(5), Sean Follmer(4), Daniel Leithinger(4), Minoru Kobayashi(4), Craig Wisneski(4), Andrew Dahley(4), Lining Yao(4), Chin-Yi Cheng(4), Alex Olwal(3), John Underkoffler(3), Scott Brave(3), James Patten(3), Wen Wang(3), Satoshi Yamaguchi(3), Kenichi Meguro(3), William Buxton(2), Matt Gorbet(2), Paul Yarin(2), Ben Piper(2)